Abbott’s Strategic Move: $21 Billion Acquisition of Exact Sciences

Shares of Abbott Laboratories experienced significant volatility following the announcement of a major acquisition in the cancer diagnostics sector. The healthcare conglomerate has revealed plans to acquire Exact Sciences Corporation in a transaction valued at approximately $21 billion, positioning itself for substantial growth in molecular diagnostics.

Under the agreement terms, Abbott will pay $105 per share in cash for Exact Sciences. The boards of directors at both corporations have unanimously approved the transaction, which is projected to finalize during the second quarter of 2026, pending standard regulatory approvals and customary closing conditions.

This acquisition brings Exact Sciences’ comprehensive molecular diagnostics portfolio under Abbott’s umbrella, including the widely recognized colorectal cancer screening Read more...